Detalles de la búsqueda
1.
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.
J Clin Immunol
; 44(7): 148, 2024 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38896141
2.
Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
J Clin Immunol
; 43(8): 2127-2135, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37773562
3.
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
J Clin Immunol
; 44(1): 28, 2023 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129731
4.
Evaluation of body weight-based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency.
Pulm Pharmacol Ther
; 83: 102265, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37923165
5.
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
J Peripher Nerv Syst
; 28(3): 436-449, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314318
6.
Comparative biochemical efficacy analysis of an alpha1-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiency.
Pulm Pharmacol Ther
; 73-74: 102124, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35314325
7.
Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
J Clin Immunol
; 41(6): 1331-1338, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34036490
8.
Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.
BMC Immunol
; 21(1): 24, 2020 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32366233
9.
Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.
Ann Allergy Asthma Immunol
; 123(3): 271-279.e1, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31228628
10.
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
J Clin Immunol
; 36(7): 700-12, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27582171
11.
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
J Clin Immunol
; 36(6): 571-82, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27220317
12.
A Novel Targeted Screening Tool for Hypogammaglobulinemia: Measurement of Serum Immunoglobulin (IgG, IgM, IgA) Levels from Dried Blood Spots (Ig-DBS Assay).
J Clin Immunol
; 35(6): 573-82, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26275445
13.
Autoimmunity and inflammation in X-linked agammaglobulinemia.
J Clin Immunol
; 34(6): 627-32, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24909997
14.
Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Int Immunopharmacol
; 128: 111447, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38185032
15.
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study.
Immunotherapy
; : 1-13, 2024 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38888495
16.
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.
Immunother Adv
; 4(1): ltae001, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38511087
17.
Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".
J Clin Immunol
; 37(8): 739-740, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28875256
18.
Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies.
Int Immunopharmacol
; 113(Pt A): 109331, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36461591
19.
Pharmacokinetics and Biochemical Efficacy of an α1-Proteinase Inhibitor (Aralast NP) in α1-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis.
Pulm Ther
; 8(3): 311-326, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36001294
20.
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases.
Immunotherapy
; 14(4): 215-224, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931880